APPENDIX D TO APPENDIX C 
II. Institutional Biohazards Committee 
Your institution must establish a standing biohazards committee. 
Suggestions for the composition of such a committee are discussed 
under Section IV of the guidelines, which also discusses the roles 
and responsibilities of principal investigators and institutions. 
A roster of your institutional biohazards committee must be sub- 
mitted to the NIH. The minimum information must include the names, 
addresses, occupations and qualifications of the chairman and 
members of the committee. This information must be submitted no 
later than October 15 to: 
Office of Recombinant Activities 
National Institute of General Medical Sciences 
National Institutes of Health 
Building 31 Roan 4A52 
Bethesda, MD 20014 
The composition of institutional biohazards committees is subject 
to review by the Office of Recombinant ENA Activities for compliance 
with recommendations stated in the guidelines. 
It is the responsibility of each grantee institution to update 
this information at least annually. 
As stipulated in the guidelines, the Office of Recombinant DNA 
Activities will assist in the formation of an area biohazards 
conmittee when this is appropriate. Such an area committee will be 
necessary when additional expertise from outside a given institution 
is necessary for the biohazards committee to fulfill its functions. 
Ill . Conduct of Experiments 
Institutions and principal investigators are responsible for taking 
immediate steps to ensure that experiments are brought into conpliance 
with the NIH guidelines. 
Effective immediately, all experiments must be conducted at the 
required level of physical containment specified in the guidelines. 
If the required level of physical containment can not be achieved, 
the experiments must be terminated until the physical containment 
required by the guidelines is available. 
Also effective immediately, all experiments to be initiated must 
use the required level of biological containment specified in the 
guidelines. For ongoing experiments, investigators will have the 
opportunity to petition the NIH Recombinant ENA Molecule Program 
Advisory Committee to use clones already in existence and constructed 
under Asilanar guidelines. However, investigators are strongly urged 
Appendix C — 21 
